drug
amifampridine phosphate
Marketedupdated 3mo agoby $CPRX CATALYST PHARMACEUTICALS, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying amifampridine phosphate
- —Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
- phase3Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
- phase3Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
- phase2Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 29, 2032
~5.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Feb 25, 2037formulationUS 10626088
- May 26, 2034method-of-use (U-2956)US 10793893
- Jun 29, 2032method-of-use (U-2956)US 11060128
- Jun 29, 2032method-of-use (U-2956)US 11268128
- Jun 29, 2032method-of-use (U-2956)US 11274331
- Jun 29, 2032method-of-use (U-2956)US 11274332
News(2)
- Angelini to buy Catalyst in $4B play for rare neuro drugsThe acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.biopharma_dive · 3mo ago
- Angelini fortifies neurology portfolio with $4.1B buyout of CatalystAngelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three medicines to Angelini’s po…endpoints · 3mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that